Please login to the form below

Not currently logged in
Email:
Password:

Dr David Chiswell joins Kymab

He takes up the role of chief executive officer

Kymab Dr David ChiswellCambridge, UK-based Kymab has appointed Dr David Chiswell as chief executive officer, a position he will take up on 1 April.

Dr Chiswell has served as interim chief executive at the drug development biotech since February 2015 when Dr Christian Grondahl stepped down from the role and as chairman of the board since September 2013.

He brings over 30 years of biotechnology expertise to the firm, having held senior management positions at a number of pharmaceutical companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei.

He co-founded Cambridge Antibody Technology in 1990 and served as its chief executive officer between 1996 and 2002 before it was acquired by AstraZeneca in 2006.

Dr Chiswell currently serves as chairman of Albireo Pharma, a Swedish biopharmaceutical company, and is a director of Nabriva Therapeutics, an Austrian biopharmaceutical firm.

He has also previously served as chairman of the UK BioIndustry Association (BIA) and was awarded the OBE in 2006 for services to the biotechnology industry.

Dr Chiswell said: “I have spent one of the most satisfying years of my career as interim CEO working closely with the excellent team at Kymab.

“I believe Kymab has all the tools needed to enable it to become a truly successful major biotech company.

“I am very pleased to be taking the helm on a permanent basis at a time when we are commencing our clinical trial programmes.”

24th March 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics